Free tool
FAERS Monitor: Cinvanti
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209296 or its brand name (Cinvanti, Aprepitant). Reports on generic versions are filed under their own applications.
Reports
7,525
Serious
7,148
95% of reports
Hospitalization
4,493
Death reported
1,480
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue1,297
- nausea1,128
- pyrexia924
- off label use889
- alopecia825
- dyspnoea824
- diarrhoea784
- rash768
- vomiting714
- hypersensitivity705
- infusion related reaction695
- pain693
- decreased appetite689
- stomatitis664
- pruritus663
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 15 |
| 2006 | 28 |
| 2007 | 24 |
| 2008 | 29 |
| 2009 | 48 |
| 2010 | 66 |
| 2011 | 105 |
| 2012 | 141 |
| 2013 | 169 |
| 2014 | 160 |
| 2015 | 228 |
| 2016 | 393 |
| 2017 | 164 |
| 2018 | 362 |
| 2019 | 447 |
| 2020 | 508 |
| 2021 | 677 |
| 2022 | 642 |
| 2023 | 763 |
| 2024 | 1,036 |
| 2025 | 905 |
| 2026 | 608 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,634 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| stomatitisSignal | 664 | 30.9 | 28.7 | 19,044 |
| infusion related reactionSignal | 695 | 29.6 | 27.6 | 19,040 |
| alopeciaSignal | 825 | 11.8 | 11.1 | 8,176 |
| hypersensitivitySignal | 705 | 10.7 | 9.9 | 6,188 |
| decreased appetiteSignal | 689 | 8.3 | 7.7 | 4,461 |
| pyrexiaSignal | 924 | 7.5 | 7.0 | 5,254 |
| rashSignal | 768 | 4.9 | 4.6 | 2,450 |
| pruritusSignal | 663 | 4.8 | 4.5 | 2,043 |
| fatigueSignal | 1,297 | 4.7 | 4.4 | 3,865 |
| vomitingSignal | 714 | 4.2 | 4.0 | 1,809 |
| dyspnoeaSignal | 824 | 4.1 | 3.8 | 1,957 |
| nauseaSignal | 1,128 | 4.0 | 3.8 | 2,617 |
| diarrhoeaSignal | 784 | 3.4 | 3.2 | 1,364 |
| painSignal | 693 | 3.2 | 2.9 | 1,048 |
| off label useSignal | 889 | 2.8 | 2.7 | 1,102 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.